Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Journal of Breast Disease

2013  (1,  1)  to  Present  ISSN: 2288-5560

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

117

results

page

of 12

1

Cite

Cite

Copy

Share

Share

Copy

Clinicopathological Factors Associated with Remnant or Regrowth of Benign Breast Tumor after Previous Vacuum-Assisted Core Biopsy.

Won Gong CHOO ; Chang Wan JEON ; Dong Won RYU

Journal of Breast Disease.2017;5(1):23-27. doi:10.14449/jbd.2017.5.1.23

PURPOSE: We sometimes encounter remnant or regrowth of benign breast tumors diagnosed as Breast Imaging-Reporting and Data System (BI-RADS) C4 in follow-up breast ultrasound after previous vacuum-assisted core biopsy (VACB). We aimed to evaluate the factors that influence remnant or regrowth tumors at post-VACB site or adjacent tissue. METHODS: From January 2010 to December 2015, we analyzed 647 cases on follow-up. Patients were divided into two groups; group A was defined as patients without recurrent masses on breast ultrasonography during the follow-up period, and group B was defined as those with recurrent masses diagnosed as more than BI-RADS C4 on ultrasonography. RESULTS: Fibrocystic changes, proliferative disease without atypia, intraductal papilloma, apocrine cell change, atypical ductal hyperplasia, sclerosing adenosis, and radial scars were observed in 89.5% (n=579), 15.9% (n=103), 15.3% (n=99), 5.3% (n=34), 5.7% (n=37), 7.6% (n=49), and 6.3% (n=41) of patients, respectively. During the follow-up period, 85 patients were diagnosed as group B. Group B was significantly associated with proliferative diseases without atypia, sclerosing adenosis, and microcalcifications compared to group A (p=0.008, p=0.007, and p=0.001, respectively). After adjustment for confounding variables, group B was more significantly associated with proliferative breast diseases than group A (hazard ratio [HR], 0.558; 95% confidence interval [CI], 0.343–0.907; p=0.018). Furthermore, group B was more significantly associated with intraductal papilloma (HR, 0.571; 95% CI, 0.342–0.953; p=0.032). CONCLUSION: Previously diagnosed proliferative diseases without atypia or microcalcification at first VACB were significantly associated with recurrent breast tumor. Intraductal papilloma was also significantly associated with tumor regrowth.
Biopsy* ; Breast Diseases ; Breast Neoplasms* ; Breast* ; Cicatrix ; Confounding Factors (Epidemiology) ; Follow-Up Studies ; Humans ; Hyperplasia ; Information Systems ; Papilloma, Intraductal ; Recurrence ; Ultrasonography ; Ultrasonography, Mammary

Biopsy* ; Breast Diseases ; Breast Neoplasms* ; Breast* ; Cicatrix ; Confounding Factors (Epidemiology) ; Follow-Up Studies ; Humans ; Hyperplasia ; Information Systems ; Papilloma, Intraductal ; Recurrence ; Ultrasonography ; Ultrasonography, Mammary

2

Cite

Cite

Copy

Share

Share

Copy

Re-Excision Rate in Breast Conservation Surgery after Neoadjuvant Chemotherapy.

Jung Hyun SONG ; Jeong Yeong PARK ; Jung Eun CHOI ; Suhwan KANG ; Soo Jung LEE ; Youngkyung BAE

Journal of Breast Disease.2017;5(1):16-22. doi:10.14449/jbd.2017.5.1.16

PURPOSE: The purpose of this study was to compare the success rate of re-excision and breast-conserving surgery (BCS) between patients who received neoadjuvant chemotherapy and those who did not. METHODS: In this retrospective cohort study, 256 women who had clinical T2 breast cancer and planned to receive, as initial treatment either BCS (n=197) or neoadjuvant chemotherapy (n=59) between January 2009 and December 2012 were included. The data, including age, initial tumor size, mammographic microcalcification, ultrasound multifocality and axillary nodal status, were collected. The pathologic tumor size, p-multifocality, histologic type, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, ductal carcinoma in situ (DCIS) and extensive intraductal component (EIC) were also reviewed. The re-excision and BCS success rates were investigated. Univariate analysis and regression model were used. To reduce the effect of selection bias, propensity score matching-based analysis was also performed. RESULTS: Of the 256 patients, 178 patients (90.4%, 178/197) in the non-neoadjuvant group and 56 patients (94.9%, 56/59) in the neoadjuvant group received BCS (p=0.406). In propensity-matched cohorts (n=118), the re-excision rate was similar in the two groups (35.6% in neoadjuvant group vs. 35.6% in non-neoadjuvant group, p=1.000). BCS success rate was slightly higher in neoadjuvant group (94.9%, 56/59) than in non-neoadjuvant group (86.4% [51/59], p=0.205). In logistic regression model, clinicopathologic factors associated with re-excision were pathologic multifocality (odds ratio [OR], 4.56; p=0.0142), high Ki-67 (≥50%) (OR, 0.7; p=0.0243) and DCIS component (OR, 2.67; p=0.0261). CONCLUSION: This study showed that neoadjuvant chemotherapy could increase the success rate of BCS but could not decrease that of re-excision. The re-excision rate is more associated with pathologic finding rather than the effect of neoadjuvant chemotherapy.
Breast Neoplasms ; Breast* ; Carcinoma, Intraductal, Noninfiltrating ; Cohort Studies ; Drug Therapy* ; Estrogens ; Female ; Humans ; Logistic Models ; Mastectomy, Segmental ; Propensity Score ; Receptor, Epidermal Growth Factor ; Receptors, Progesterone ; Retrospective Studies ; Selection Bias ; Ultrasonography

Breast Neoplasms ; Breast* ; Carcinoma, Intraductal, Noninfiltrating ; Cohort Studies ; Drug Therapy* ; Estrogens ; Female ; Humans ; Logistic Models ; Mastectomy, Segmental ; Propensity Score ; Receptor, Epidermal Growth Factor ; Receptors, Progesterone ; Retrospective Studies ; Selection Bias ; Ultrasonography

3

Cite

Cite

Copy

Share

Share

Copy

Distress Screening and Management in Early Breast Cancer Patients: Distress after Breast Cancer Diagnosis and Associated Factors.

Hyunnam BAEK ; Eunyoung KANG ; Angela Soeun LEE ; Euijun HWANG ; Sumin CHAE ; Eun Kyu KIM ; Sung Won KIM

Journal of Breast Disease.2017;5(1):8-15. doi:10.14449/jbd.2017.5.1.8

PURPOSE: The aims of this study were to evaluate the magnitude of distress after breast cancer diagnosis and to investigate factors associated with distress, as well as to determine the effectiveness of psychological intervention. METHODS: This study was performed retrospectively, reviewing 264 patients who underwent breast cancer surgery at Seoul National University Bundang Hospital between November 2011 and May 2014. Distress was measured using the distress thermometer (DT) and Center for Epidemiological Studies-Depression scale (CES-D) questionnaires before, as well as at 3 and 6 months postsurgery. Psychological intervention was recommended to high risk patients (DT score ≥5 or CES-D score ≥16). RESULTS: In total, 149 patients (56.4%) were classified as high risk in the initial assessment. In the following assessments, the proportion of those in the high risk group was 38.5% and 25.0% at 3 and 6 months postsurgery, respectively. Mastectomy was significantly associated with high levels of distress compared to breast-conserving surgery in the univariate (p=0.048) and multivariate analyses (p=0.014). However, there was no significant relationship between any of the various socioeconomic factors and distress. Distress level was reduced over time in both scales. Of the 149 high risk patients, only 21 received the psychological intervention. Using linear mixed models, the psychological intervention resulted in marginally significant reductions in DT (p=0.051) and CES-D (p=0.077) scores. CONCLUSION: More than half of patients experienced distress upon initial diagnosis, and the determined surgery type was an important factor associated with high distress level. It is important to identify high risk patients and to manage distress during the initial phase.
Breast Neoplasms* ; Breast* ; Diagnosis* ; Humans ; Mass Screening* ; Mastectomy ; Mastectomy, Segmental ; Multivariate Analysis ; Retrospective Studies ; Seoul ; Socioeconomic Factors ; Thermometers ; Weights and Measures

Breast Neoplasms* ; Breast* ; Diagnosis* ; Humans ; Mass Screening* ; Mastectomy ; Mastectomy, Segmental ; Multivariate Analysis ; Retrospective Studies ; Seoul ; Socioeconomic Factors ; Thermometers ; Weights and Measures

4

Cite

Cite

Copy

Share

Share

Copy

Factors Associated with Metastatic Breast Cancer in Patients Who Show Long-Term Stable Disease Status.

Young Hoon NOH ; Yun Gyoung KIM1 ; Ji Hyun KIM ; Hyang Suk CHOI ; Seok Joon LEE ; Jae Sung KIM ; In Chul PARK ; Min Ki SEONG ; Hyun Ah KIM ; Woo Chul NOH

Journal of Breast Disease.2017;5(1):1-7. doi:10.14449/jbd.2017.5.1.1

PURPOSE: This study aimed to analyze the basic clinical characteristics and survival of patients with breast cancer whose disease had been stably maintained for more than 24 months after systemic therapy. METHODS: We retrospectively reviewed the medical records of patients with primary breast cancer who underwent surgery. Among these patients, patients with stage IV disease at diagnosis or those who developed distant metastasis during the follow-up period after surgery were included in this analysis. Patients whose disease remained stable for more than 24 months were classified as the long-term stable disease group. The remaining patients were classified as the control group. RESULTS: A total of 245 patients were eligible for this analysis. Patients in the long-term stable disease group showed a lower rate of histologic type III, a higher rate of hormone receptor positivity, and received less adjuvant chemotherapy. In the long-term stable disease group, the most frequent site of metastasis was the lungs, whereas in the control group, it was the bones. Overall survival was significantly better in the long-term stable disease group than in the control group (p<0.001). In univariate analysis, factors affecting the overall survival rate were the duration from diagnosis to metastasis, the absence of lymphatic infiltration, and the presence of hormone receptors. In multivariate analysis, the duration from diagnosis to metastasis and the absence of lymphatic infiltration were significant factors affecting the overall survival rate. CONCLUSION: Disease progression was observed in many patients even after the disease had been stable for more than 24 months after systemic therapy. Although these patients had better outcomes compared with the others, continuous observation and possible additional treatment might be helpful for some patients.
Breast Neoplasms* ; Breast* ; Chemotherapy, Adjuvant ; Diagnosis ; Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Lung ; Medical Records ; Multivariate Analysis ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies ; Survival Rate ; Survivors

Breast Neoplasms* ; Breast* ; Chemotherapy, Adjuvant ; Diagnosis ; Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Lung ; Medical Records ; Multivariate Analysis ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies ; Survival Rate ; Survivors

5

Cite

Cite

Copy

Share

Share

Copy

The Results of Occult Breast Carcinoma Treated with Axillary Node Dissection Only: Five Cases Reports.

Youngmin KIM ; Hyosun KIM ; Jihyoung CHO ; Sunyoung KWON ; Soohyun YEO ; Sun Hee KANG

Journal of Breast Disease.2016;4(1):24-27. doi:10.14449/jbd.2016.4.1.24

Herein, we report five cases of occult breast cancer treated with axillary node dissection only, without breast surgery or whole breast radio-therapy. The patients complained of a large, hard mass in the axillary area, although no breast masses were palpable. Biopsy of the axillary mass was performed in each case, and histological examination showed a metastatic carcinoma. No malignant findings were observed by mammography or ultrasonography. Magnetic resonance imaging and systemic examinations revealed no extramammary primary lesions. All patients underwent axillary lymph node dissection without breast surgery, and were administered adjuvant chemotherapy but not whole breast radiation therapy. The median follow-up period was 56 months (range, 15–241 months). The patients were all alive with no evidence of disease at the end of the follow-up period.
Axilla ; Biopsy ; Breast Neoplasms* ; Breast* ; Chemotherapy, Adjuvant ; Follow-Up Studies ; Humans ; Lymph Node Excision ; Magnetic Resonance Imaging ; Mammography ; Neoplasms, Unknown Primary ; Ultrasonography

Axilla ; Biopsy ; Breast Neoplasms* ; Breast* ; Chemotherapy, Adjuvant ; Follow-Up Studies ; Humans ; Lymph Node Excision ; Magnetic Resonance Imaging ; Mammography ; Neoplasms, Unknown Primary ; Ultrasonography

6

Cite

Cite

Copy

Share

Share

Copy

Predictors for the Transition from Ductal Carcinoma In Situ to Invasive Breast Cancer in Korean Patients.

Eun Young KIM ; Kee Hoon HYUN ; Yong Lai PARK ; Chan Heun PARK ; Sung Im DO

Journal of Breast Disease.2016;4(1):16-23. doi:10.14449/jbd.2016.4.1.16

PURPOSE: To identify predictive factors of upstaging from diagnosed ductal carcinoma in situ (DCIS) to invasive cancer after surgical excision. METHODS: One hundred seventy-four patients diagnosed with DCIS based on biopsies between January 2009 and December 2014 were evaluated. Patients' clinicopathological variables were assessed to identify predictive factors of invasive carcinoma from final pathology. RESULTS: One hundred seventy-four cases of DCIS were included. Of these, 42 were upstaged to invasive carcinoma on the final excision. Preoperative features such as age 40 years or younger at diagnosis, presence of a palpable mass, ultrasonography (USG)-guided core needle biopsy, tumor size ≥20 mm on USG, high grade DCIS, cribriform DCIS, comedo necrosis, presence of intraluminal calcification, estrogen receptor negativity, progesterone receptor negativity and triple-negative subtype were significantly associated with the risk of invasive carcinoma. Multivariate analysis showed that a tumor size ≥20 mm on USG and triple negative subtype were independently associated with upstaging. CONCLUSION: Tumor size ≥20 mm on USG and triple-negative subtype were independently associated with the upstaging of DCIS to invasive cancer.
Biopsy ; Biopsy, Large-Core Needle ; Breast Neoplasms* ; Breast* ; Carcinoma, Ductal* ; Carcinoma, Intraductal, Noninfiltrating* ; Diagnosis ; Estrogens ; Humans ; Multivariate Analysis ; Necrosis ; Pathology ; Receptors, Progesterone ; Ultrasonography

Biopsy ; Biopsy, Large-Core Needle ; Breast Neoplasms* ; Breast* ; Carcinoma, Ductal* ; Carcinoma, Intraductal, Noninfiltrating* ; Diagnosis ; Estrogens ; Humans ; Multivariate Analysis ; Necrosis ; Pathology ; Receptors, Progesterone ; Ultrasonography

7

Cite

Cite

Copy

Share

Share

Copy

Clinicopathologic Features of Pleomorphic Invasive Lobular Carcinoma: Comparison with Classic Invasive Lobular Carcinoma.

Changho YEOM ; Hyosun KIM ; Sunyoung KWON ; Sun Hee KANG

Journal of Breast Disease.2016;4(1):10-15. doi:10.14449/jbd.2016.4.1.10

PURPOSE: The purpose of this study was to identify the clinical and pathological factors that differentiate pleomorphic invasive lobular carcinoma (PILC) from classic invasive lobular carcinoma (CILC). METHODS: We retrospectively reviewed the medical records of 65 patients (4.0% of all invasive breast cancer patients) who underwent surgical excision for invasive lobular carcinoma (ILC) between January 2000 and November 2013. All 65 patients were diagnosed with ILC with negative immunohistochemical staining for E-cadherin in the tumor cells. All hematoxylin and eosin slides of the previously diagnosed ILC were reviewed and confirmed by two expert pathologists and we compared the clinicopathologic features between CILC and PILC. RESULTS: CILC was found in 46 cases and PILC, in 19 cases. Of the mammographic findings, a mass or asymmetric density was the most common feature (42.3% of all ILC patients). The most common ultrasonographic feature was a mass (94.9% of all ILC patients). Tumor multiplicity was noted in 10 patients (15.4%) among all ILC patients; eight patients (17.4%) had CILC and two patients (10.5%) had PILC. PILC patients had more grade III tumors (66.7% vs. 8.7%, p=0.002) and a higher Ki-67 labeling index (55.6% vs. 18.6%, p=0.004) than those with CILC. There were no statistical differences in the type of combined in situ component, extensive intraductal component, tumor size, lymphovascular invasion, stage, hormone receptor status, human epidermal growth factor receptor 2 status, distribution of intrinsic subtype, or imaging findings. Moreover, there was no significant difference in survival between CILC and PILC. CONCLUSION: PILC showed more pathological aggressiveness than CILC in terms of tumor grade and Ki-67 index.
Breast ; Breast Neoplasms ; Cadherins ; Carcinoma, Lobular* ; Eosine Yellowish-(YS) ; Hematoxylin ; Humans ; Medical Records ; Receptor, Epidermal Growth Factor ; Retrospective Studies

Breast ; Breast Neoplasms ; Cadherins ; Carcinoma, Lobular* ; Eosine Yellowish-(YS) ; Hematoxylin ; Humans ; Medical Records ; Receptor, Epidermal Growth Factor ; Retrospective Studies

8

Cite

Cite

Copy

Share

Share

Copy

Clinical Implications of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in the Era of Genomic Medicine: Clinician's Perspectives.

Hyung Seok PARK ; Ji Soo PARK ; Eun Ji NAM ; Seung Tae LEE ; Jung Woo HAN ; Tae Il KIM

Journal of Breast Disease.2016;4(1):1-9. doi:10.14449/jbd.2016.4.1.1

Hereditary breast and ovarian cancer syndrome accounts for approximately 5% to 10% of breast or ovarian cancers, with which the high-penetrant BRCA1/2 genes have been associated. With the recent development of next-generation sequencing (NGS), germline mutation testing and its related medical and surgical management have been rapidly changing. In this review, we summarize the current status and perspectives of NGS testing for not only BRCA1/2 but also the other breast and ovarian cancer susceptibility genes.
Breast ; Breast Neoplasms ; Genetic Testing* ; Germ-Line Mutation ; Hereditary Breast and Ovarian Cancer Syndrome* ; High-Throughput Nucleotide Sequencing ; Ovarian Neoplasms

Breast ; Breast Neoplasms ; Genetic Testing* ; Germ-Line Mutation ; Hereditary Breast and Ovarian Cancer Syndrome* ; High-Throughput Nucleotide Sequencing ; Ovarian Neoplasms

9

Cite

Cite

Copy

Share

Share

Copy

Retrospective Analysis of Idiopathic Granulomatous Mastitis: Its Diagnosis and Treatment.

Jinwoo JEON ; Kyunghee LEE ; Yunyeong KIM ; Yong Soon CHUN ; Heung Kyu PARK

Journal of Breast Disease.2017;5(2):82-88. doi:10.14449/jbd.2017.5.2.82

PURPOSE: Idiopathic granulomatous mastitis (IGM) is a rare disease characterized by noncaseating granulomatous inflammation of unknown origin. Because its clinical features are similar to those of other type of mastitis or breast cancer, accurate diagnosis and adequate treatment are essential to ensuring a short symptom duration and improving the quality of life. METHODS: The clinical, radiologic, pathophysiologic, and treatment data for 43 patients diagnosed with IGM at the Breast Cancer Center of Gachon University Gil Medical Center between 2005 and 2016 were retrospectively reviewed. RESULTS: Forty-one patients (95.34%) were of childbearing age, seven (16.27%) had a history of lactation, and five (11.62%) had a history of oral contraceptive use. In terms of radiologic findings, 30 patients (69.77%) were diagnosed with Breast Imaging-Reporting and Data System category ≥4A lesions. Corticosteroid therapy was administered to 36 patients (83.72%); overall, 18 patients (41.86%) did not require surgery and 25 patients (58.13%) underwent partial or total mastectomy. Twelve patients (27.90%) developed recurrence. CONCLUSION: IGM is a benign disease that can be misdiagnosed as breast cancer because of its similar clinical and radiologic findings. Proper diagnosis and treatment can be difficult, but delays may lead to prolonged pain and cosmetic and socioeconomic problems. Efforts should be aimed at establishing the cause of IGM and developing efficient protocols for its diagnosis and treatment.
Breast ; Breast Neoplasms ; Diagnosis* ; Female ; Granulomatous Mastitis* ; Humans ; Immunoglobulin M ; Inflammation ; Information Systems ; Lactation ; Mastectomy, Simple ; Mastitis ; Quality of Life ; Rare Diseases ; Recurrence ; Retrospective Studies* ; Steroids

Breast ; Breast Neoplasms ; Diagnosis* ; Female ; Granulomatous Mastitis* ; Humans ; Immunoglobulin M ; Inflammation ; Information Systems ; Lactation ; Mastectomy, Simple ; Mastitis ; Quality of Life ; Rare Diseases ; Recurrence ; Retrospective Studies* ; Steroids

10

Cite

Cite

Copy

Share

Share

Copy

Synchronous Presentation of Ductal Carcinoma In Situ of the Breast with Follicular Lymphoma.

Eun Young KIM ; Sung Im DO ; Yong Lai PARK ; Chan Heun PARK

Journal of Breast Disease.2017;5(2):89-92. doi:10.14449/jbd.2017.5.2.89

A synchronous incidence of breast cancer and follicular lymphoma (FL) is uncommon. The association between these two conditions could be explained by the antigenic stimulation of the adjacent carcinoma and common genetic background. This study aimed to review the literature, and discuss the etiology and management of synchronous breast cancer and FL. Herein, we presented a case of synchronous ductal carcinoma in situ (DCIS) of the breast and FL involving multiple lymph nodes, including those in both axilla. A 49-year-old woman presented with palpable lumps in both axilla. She underwent lumpectomy, radiotherapy, and hormonal therapy for DCIS, while adjuvant chemotherapy was recommended for the lymphoma. Diagnosis was based on histopathologic analysis, such as excision or biopsy.
Axilla ; Biopsy ; Breast Neoplasms ; Breast* ; Carcinoma, Ductal* ; Carcinoma, Intraductal, Noninfiltrating* ; Chemotherapy, Adjuvant ; Diagnosis ; Female ; Genetic Background ; Humans ; Incidence ; Lymph Nodes ; Lymphoma ; Lymphoma, Follicular* ; Mastectomy, Segmental ; Middle Aged ; Radiotherapy

Axilla ; Biopsy ; Breast Neoplasms ; Breast* ; Carcinoma, Ductal* ; Carcinoma, Intraductal, Noninfiltrating* ; Chemotherapy, Adjuvant ; Diagnosis ; Female ; Genetic Background ; Humans ; Incidence ; Lymph Nodes ; Lymphoma ; Lymphoma, Follicular* ; Mastectomy, Segmental ; Middle Aged ; Radiotherapy

Country

Republic of Korea

Publisher

Korean Breast Cancer Society

ElectronicLinks

https://www.jbd.or.kr

Editor-in-chief

Min Ho Park

E-mail

jbd.editorial@gmail.com

Abbreviation

J Breast Dis

Vernacular Journal Title

ISSN

2288-5560

EISSN

Year Approved

2017

Current Indexing Status

Currently Indexed

Start Year

2013

Description

Journal of Breast Disease is official journal of Korean Breast Cancer Society, published biannually in on-line. The journal focuses on basic and clinical research for various breast diseases including breast cancer.

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.